[Current therapy of peptic ulcer].

D. Rachmilewitz

1986-02-16

Abstract:

What problem does this paper attempt to address?

Pharmacological Treatment of Peptic Ulcer Disease

Maciej Sałaga,Paula Mosińska

DOI: https://doi.org/10.1007/978-3-319-59885-7_5

2017-01-01

Abstract:Peptic ulcer disease (PUD) is an upper gastrointestinal (GI) disorder with complex etiology, which is a growing major concern worldwide. The pathophysiology of PUD is relatively well understood, hence there are several specific treatment options for this disorder aiming at various pharmacological targets located in the GI tract. In this chapter we provide an overview on pharmacological targets as well as drugs that are currently available for PUD therapy with regard to the etiology of the disease. We discuss their mechanisms of action, evidences for their effectiveness emerging from clinical trials as well as virtues and drawbacks of the most commonly prescribed medications. Furthermore, we highlight the practical aspects of the use of drugs in PUD, such as dosing regimens, resistance issues, possible adverse events, and contraindications.
Recent Advances in Molecular Pathways and Therapeutic Implications for Peptic Ulcer Management: A Comprehensive Review

Deepak Chandra Joshi,Nirmal Joshi,Ajeet Kumar,Shubhrat Maheshwari

DOI: https://doi.org/10.1055/a-2256-6592

2024-03-12

Hormone and Metabolic Research

Abstract:Peptic ulcers, recognized for their erosive impact on the gastrointestinal mucosa, present a considerable challenge in gastroenterology. Epidemiological insights underscore the global prevalence of peptic ulcers, affecting 5–10+% of individuals, with a yearly incidence of 0.3 to 1.9 cases per thousand. Recent decades have witnessed a decline in complications, attributed to improved diagnostics and therapeutic advancements. The review deepens into H. pylori -associated and NSAID-induced ulcers, emphasizing their distinct prevalence in developing and industrialized nations, respectively. Despite advancements, managing peptic ulcers remains challenging, notably in H. pylori -infected individuals facing recurrence and the rise of antibiotic resistance. The pathophysiology unravels the delicate balance between protective and destructive factors, including the intricate molecular mechanisms involving inflammatory mediators such as TNF-α, ILs, and prostaglandins. Genetic and ethnic factors, rare contributors, and recent molecular insights further enhance our understanding of peptic ulcer development. Diagnostic approaches are pivotal, with upper gastrointestinal endoscopy standing as the gold standard. Current treatment strategies focus on H. pylori eradication, NSAID discontinuation, and proton pump inhibitors. Surgical options become imperative for refractory cases, emphasizing a comprehensive approach. Advances include tailored H. pylori regimens, the emergence of vonoprazan, and ongoing vaccine development. Challenges persist, primarily in antibiotic resistance, side effects of acid suppressants, and translating natural compounds into standardized therapies. Promising avenues include the potential H. pylori vaccine and the exploration of natural compounds, with monoterpenes showing therapeutic promise. This review serves as a compass, guiding healthcare professionals, researchers, and policymakers through the intricate landscape of peptic ulcer management. Received: 21 December 2023 Accepted: 16 January 2024 Article published online: 11 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

endocrinology & metabolism
Unravelling Peptic Ulcers: Comprehensive Insights into Etiology, Diagnosis, Screening Techniques, and Treatment

Rashmi Pathak,Phool Chandra,Neetu Sachan

DOI: https://doi.org/10.2174/0113816128310979240828102727

IF: 3.31

2024-09-26

Current Pharmaceutical Design

Abstract:The risk of illnesses is increasing in the modern era due to unhealthy and modern lifestyles. Research has shown that the most frequent acid-induced abrasion, which often occurs in the stomach and proximal duodenum, is gastric and Peptic Ulcer Disease (PUD), which is a primary worldwide health concern. The deformity is characterized by denuded mucosa and spreads into the submucosa. Non-steroidal antiinflammatory drugs (NSAIDs) and H. pylori infections are two common offenders. In the past, it...

pharmacology & pharmacy
Maternal consequences of caesarean section. A retrospective study of intra-operative and postoperative maternal complications of caesarean section during a 10-year period.

M. Ham,P. Dongen,J. Mulder

DOI: https://doi.org/10.1016/S0301-2115(97)02725-5

1997-07-01

Abstract:
Peptic Ulcer: Chapter Closed?

Peter Malfertheiner,Christian Schulz

DOI: https://doi.org/10.1159/000505367

2020-01-01

Digestive Diseases

Abstract:The incidence of peptic ulcer disease (PUD) peaked in the late 19th century while transiting into the 20th century. With entry in the new millennium a significant decrease of PUD has occurred. However, demographic changes with an increasing elderly population associated with multiple comorbidities and polypharmacy became responsible for a persistent high rate of peptic ulcer complications. The acid driven concept of PUD has directed the development of surgical procedures and drugs with an increasing potency in acid suppression. High speed of symptom resolution and rapid ulcer healing was obtained with the introduction of proton pump inhibitors, but cure of PUD has failed. The arrival of Helicobacter pylori has revolutionized the history of PUD which has become a curable disease by successful cure of the infection. However, new challenges have emerged with an increase of treatment failures due to increasing antibiotic resistance of H. pylori. The changing pattern in the prevalence of etiologies other than H. pylori demands for accurate identification of the ulcerogenic cause in the individual patient to allow for proper selection of therapy. Management of peptic ulcer bleeding remains a critical clinical challenge. The chapter of PUD is reduced in size and has become more heterogeneous – but is not closed!

gastroenterology & hepatology
Therapeutic Management of Recurrent Peptic Ulcer Disease

Raymond S. Tang,Francis K. L. Chan

DOI: https://doi.org/10.2165/11634850-000000000-00000

2012-01-01

Drugs

Abstract:The epidemiology of peptic ulcer disease (PUD) has undergone significant changes since the discovery of Helicobacter pylori. Various aetiologies contribute to recurrent PUD. Ulcers related to untreated H. pylori infection tend to recur. Use of NSAIDs, low-dose aspirin and dual anti-platelet therapy have become important risk factors for recurrent ulcers and their complications as the proportion of H. pylori-related ulcers declines. Recent data have shown that H. pylori-negative, NSAID-negative idiopathic peptic ulcers are on the rise and carry a higher risk of recurrent ulcer bleeding and mortality. Effective management of recurrent PUD relies on identification and modification of treatable risk factors. Persistent H. pylori infection should be carefully ruled out. Choice of an effective H. pylori eradication regimen should be based on local antibacterial resistance patterns. For patients who need long-term NSAID therapy, the initial choice of an NSAID relates to a patient's cardiovascular risk, and the need for therapy to decrease gastrointestinal (GI) complications is determined by the severity and number of GI risk factors. For patients on dual anti-platelet therapy, strategies to prevent recurrent ulcer disease and its complications centre on balancing the bleeding and thrombotic risks of individual patients. Long-term proton pump inhibitor maintenance therapy may be necessary to prevent recurrent ulcer bleeding for patients with ulcer bleeding from H. pylori-negative, NSAID-negative ulcers, and for patients who require NSAID or aspirin maintenance therapy.
Eradication of Helicobacter pylori: recent advances in treatment

Ramona M. McLoughlin,Colm A. O'Morain,Humphrey J. O'Connor

DOI: https://doi.org/10.1111/j.1472-8206.2005.00340.x

2005-08-01

Fundamental and Clinical Pharmacology

Abstract:Helicobacter pylori plays a key role in dyspepsia, peptic ulcer disease, and gastric neoplasia and eradication of the infection has become an important treatment goal in clinical practice. Seven-day proton-pump inhibitor-amoxicillin-clarithromycin triple therapy is the current first-line therapy for H. pylori but eradication rates are compromised by poor compliance and antibiotic resistance. Ten-day sequential treatment may emerge as an alternative first-line therapy. Bismuth-based quadruple therapy is the second-line regimen of choice. Antimicrobial sensitivity testing is not recommended in the routine management of H. pylori infection. Novel triple-therapy regimens containing rifabutin, levofloxacin, or furazolidone may be useful alternatives as second- or third-line therapy.

pharmacology & pharmacy
Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options

Lucija Kuna,Jelena Jakab,Robert Smolic,Nikola Raguz-Lucic,Aleksandar Vcev,Martina Smolic

DOI: https://doi.org/10.3390/jcm8020179

IF: 3.9

2019-02-03

Journal of Clinical Medicine

Abstract:Peptic ulcer is a chronic disease affecting up to 10% of the world’s population. The formation of peptic ulcers depends on the presence of gastric juice pH and the decrease in mucosal defenses. Non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori (H. pylori) infection are the two major factors disrupting the mucosal resistance to injury. Conventional treatments of peptic ulcers, such as proton pump inhibitors (PPIs) and histamine-2 (H2) receptor antagonists, have demonstrated adverse effects, relapses, and various drug interactions. On the other hand, medicinal plants and their chemical compounds are useful in the prevention and treatment of numerous diseases. Hence, this review presents common medicinal plants that may be used for the treatment or prevention of peptic ulcers.

medicine, general & internal
Gastrointestinal Conditions: Peptic Ulcer Disease

Justin M Bailey

Abstract:Peptic ulcer disease (PUD) involves ulceration of the mucosa in the stomach and/or proximal duodenum. The main causes are Helicobacter pylori infection and nonsteroidal anti-inflammatory drug (NSAID) use. PUD occurs in 5% to 10% of people worldwide, but rates have decreased by more than half during the past 20 years. This reduction is thought to be because of H pylori management, more conservative use of NSAIDs, and/or widespread use of proton pump inhibitors (PPIs). Common symptoms include postprandial abdominal pain, nausea, vomiting, and weight loss. These symptoms have broad overlap with those of other conditions, making clinical diagnosis difficult. Endoscopy is the gold standard for diagnosis, especially in older patients and those with alarm symptoms, but a test-and-treat strategy (noninvasive test for H pylori and treat if positive) can be used for younger patients with no alarm symptoms. Numerous treatment regimens are available, all of which include PPIs plus antibiotics. As an alternative to PPIs, a new triple therapy with vonoprazan (which blocks acid production) plus antibiotics has been approved and appears to be superior to conventional therapy with PPIs plus antibiotics. At least 4 weeks after treatment, repeat testing for H pylori should be obtained to confirm cure. When possible, NSAIDs should be discontinued; when not possible, antisecretory cotherapy should be considered.
Treatment of Helicobacter pylori infection: Current and future insights

Maliheh Safavi

DOI: https://doi.org/10.12998/wjcc.v4.i1.5

2016-01-01

World Journal of Clinical Cases

Abstract:Helicobacter pylori (H. pylori) is an important major cause of peptic ulcer disease and gastric malignancies such as mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma worldwide. H. pylori treatment still remains a challenge, since many determinants for successful therapy are involved such as individual primary or secondary antibiotics resistance, mucosal drug concentration, patient compliance, side-effect profile and cost. While no new drug has been developed, current therapy still relies on different mixture of known antibiotics and anti-secretory agents. A standard triple therapy consisting of two antibiotics and a proton-pump inhibitor proposed as the first-line regimen. Bismuth-containing quadruple treatment, sequential treatment or a non-bismuth quadruple treatment (concomitant) are also an alternative therapy. Levofloxacin containing triple treatment are recommended as rescue treatment for infection of H. pylori after defeat of first-line therapy. The rapid acquisition of antibiotic resistance reduces the effectiveness of any regimens involving these remedies. Therefore, adding probiotic to the medications, developing anti-H. pylori photodynamic or phytomedicine therapy, and achieving a successful H. pylori vaccine may have the promising to present synergistic or additive consequence against H. pylori, because each of them exert different effects.

medicine, general & internal
Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice

Logan T. Roberts,Peter P. Issa,Evan S. Sinnathamby,Mallory Granier,Holly Mayeux,Treniece N. Eubanks,Kevin Malone,Shahab Ahmadzadeh,Elyse M. Cornett,Sahar Shekoohi,Alan D. Kaye

DOI: https://doi.org/10.3390/life12122038

2022-12-07

Life

Abstract:Background: When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations. Helicobacter pylori is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment. Due to constantly fluctuating resistance rates, regimens must be constantly assessed to ensure effectiveness. Methods: This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords: Helicobacter pylori, Treatment Options, Clinical Practice. Results: Multiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered. Conclusions: This review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient.
Actualization of the modern approach to the treatment of gastric ulcer

Roman Petrovich Stepchenkov,

DOI: https://doi.org/10.33920/med-10-2206-08

2022-06-05

Spravočnik vrača obŝej praktiki (Journal of Family Medicine)

Abstract:Despite the generally accepted fact that Helicobacter pylori is the main cause of gastric and duodenal ulcers, its role is not always decisive. It was found that this pathogen does not have a sufficient level of invasiveness, and in about 70% of cases does not lead to morphological disorders of the gastric and intestinal mucosa. Speaking about the possible causes of the development of peptic ulcer, one cannot but take into account the influence of stressful situations, aggravated heredity, and nutritional errors. One of the urgent problems of modern medicine is to increase the effectiveness of peptic ulcer treatment and prevent recurrence of the disease, and the main direction of antiulcer therapy is the eradication of Helicobacter pylori with the parallel administration of antisecretory drugs. Meanwhile, it should be noted that the lack of certainty in matters of pathogenesis over a number of years led to the unreasonable prescription of a large number of various medications, ranging from antacids and antispasmodics to sedatives and tranquilizers. Such a wide variety of therapeutic drugs used indicates that for a long time it was not possible to confirm the real effectiveness and clinical efficacy of most antiulcer drugs, which once again confirmed the correctness of the phrase said by the famous therapist V.Kh. Vasilenko regarding the fact that "gastroduodenal ulcers heal due to treatment, despite treatment and even in spite of treatment".
Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review

P. Cortés,Yan Bi,G. Pujalte,A. Nelson,D. Harris,V. Gómez,Loren Murray,F. Stancampiano

DOI: https://doi.org/10.1177/21501327211014087

2021-05-05

Journal of Primary Care & Community Health

Abstract:H. pylori is the most common infection in the world and is associated with gastrointestinal and extra-gastrointestinal manifestations, including peptic ulcer disease, gastrointestinal bleeding, and lymphoproliferative disorders. Despite being discovered less than half a century ago, antibiotic resistance, exacerbated by medication non-adherence and inefficacy of proton pump inhibitors, has grown substantially, explaining the rising incidence of refractory H. pylori infection. In this review, we discuss risk factors, treatment options, surveillance and follow-up, as well as emerging therapies for refractory H. pylori.

Medicine
An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults

V Prabhu,A Shivani

DOI: https://doi.org/10.4103/2141-9248.126604

2014-01-01

Annals of Medical and Health Sciences Research

Abstract:Peptic ulcer disease including both gastric and duodenal ulcer form a substantial part of patients seeking surgical opinion world-wide. The concept of acid in peptic ulcer disease, which was the basis of treatment of peptic ulcer was revolutionized by the discovery of H2-receptor antagonists, that led to the principle of acid suppression therapy for duodenal ulcer which followed decades of preference for surgical interventions in the form of gastric resections, vagotomy etc., After the discovery of Helicobacter pylori organism as the causative factor a triple drug regime was identified to treat peptic disease which was further modified to sequential therapy to avoid antibiotic resistance. This recognition has not concluded the chapter on peptic ulcers. The management of ulcer disease and its complications remain a surgical challenge. All the materials for this review have been accessed from various internet search engines. The references have been narrowed down to 34 by excluding cross references, duplicated citations, pediatric studies, case reports, iatrogenic and malignant perforations and including microbiological, immunohistochemistry references and studies with more than a sample size of ten. Case control, cohort studies, prospective/retrospective, metaanalytical studies were preferred in that order. This article attempts to take an overview of all aspects of the management of peptic ulcer.
From Lab to Nature: Recent Advancements in the Journey of Gastroprotective Agents from Medicinal Chemistry to Phytotherapy

Susmita Yadav,Anima Pandey,Suraj N. Mali

DOI: https://doi.org/10.1016/j.ejmech.2024.116436

IF: 7.088

2024-04-24

European Journal of Medicinal Chemistry

Abstract:Peptic ulcer, affecting 10% of the global population, results from imbalances in gastric juice pH and diminished mucosal defences. Key underlying factors are non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection, undermining mucosal resistance. Traditional treatments like proton pump inhibitors (PPIs) and histamine-2 (H2) receptor antagonists exhibit drawbacks such as adverse effects, relapses, and drug interactions. This review extensively explores the ethnomedicinal, synthetic and pharmacological facets of various potential peptic ulcer treatments. Rigorous methodologies involving electronic databases, and chemical structure verification via 'PubChem' and 'SciFinder' enhance the review's credibility. The provided information, spanning medicinal insights to intricate pharmacological mechanisms, establishes a robust groundwork for future research and the development of plant-derived or synthetic molecules for peptic ulcers, offering a promising alternative to conventional therapies.

chemistry, medicinal
Comprehensive insights on treatment modalities with conventional and herbal drugs for the treatment of duodenal ulcers

DOI: https://doi.org/10.1007/s00210-024-03178-5

2024-06-06

Naunyn-Schmiedeberg s Archives of Pharmacology

Abstract:Areas of the body accessible to gastric secretions, such as the stomach and duodenum, are most commonly damaged by circumscribed lesions of the upper gastrointestinal tract mucosa. Peptic ulcer disease is the term for this illness (PUD). About 80% of peptic ulcers are duodenal ulcers, with stomach ulcers accounting for the remaining 20%. Duodenal ulcers are linked to the two primary results about Helicobacter pylori infection and COX inhibitor users. Additional causes might include drinking, smoking, stress, and coffee consumption. The indications and symptoms of a duodenal ulcer depend on the patient's age and the lesion's location. For duodenal ulcers, proton pump inhibitors (PPIs) are the usual course of treatment. This comprehensive study included an in-depth literature search in the literature and methods section using electronic databases such as PubMed, ScienceDirect, and Google Scholar. The search method included publications published from the inception of the relevant database to the present. Inclusion criteria included studies investigating different treatment options for duodenal ulcer disease, including traditional pharmacotherapy and naturopathic treatments. Data mining includes information on treatment techniques, treatment outcomes, and possible synergies between conventional and herbal treatments. In addition, this review critically examines the available information on the effectiveness, safety, and possible side effects of different treatments. The inclusion of conventional and herbal treatments is intended to provide a comprehensive overview of the many treatment options available for duodenal ulcer disease. A more comprehensive and personalized treatment plan can be achieved by incorporating dietary changes, lifestyle modifications, and, if necessary, herbal therapies to complement other treatments normally.

pharmacology & pharmacy
Turn over the new leaf of the treatment in peptic ulcer bleeding: a review of the literature

Meng-Hsuan Lu,Hsueh-Chien Chiang

DOI: https://doi.org/10.1177/17562848241275318

2024-09-08

Abstract:Peptic ulcer bleeding is the most common cause of upper gastrointestinal bleeding, which has a high mortality risk. The standard therapy for acute peptic ulcer bleeding combines medication administration and endoscopic therapies. Both pharmacologic and endoscopic therapies have developed continuously in the past few decades. Proton pump inhibitors (PPIs) already reached a high efficacy in ulcer healing and have been widely used in the past few decades. Endoscopic hemostasis, which includes local epinephrine injection, heater probe coagulation, use of hemostatic clips, and/or band ligation, is highly effective with an overall hemostatic success rate of 85%-90%. However, 10%-20% of patients could not be cured by the current standard combination treatment. Recurrent ulcer bleeding, despite an initial successful hemostasis, is also a big problem for longer hospitalization stays, higher mortality, and higher complication rates, especially for malignant ulcer bleeding. How to manage all types of peptic ulcer bleeding and how to prevent early recurrent peptic ulcer bleeding remain unresolved clinical problems. Recently, several novel medications and endoscopic methods have been developed. Potassium competitive acid blockers have shown a stronger and longer acid suppression than PPI. Hemostatic powder spray and hemostatic gel emulsion are novel hemostatic weapons with emerging evidence, which are potential missing pieces of the puzzle. This literature review will go through the development of endoscopic hemostasis to the prospects of novel endoscopic treatments.
Current and Future Drugs for Acid-Peptic Disease: A Plethora of Opinions on Possible Mechanisms of Action

J Dent,R F McCloy,A Garner,J B Matthews,S Rune,A L Blum,John Dent,Rory F. McCloy,Andrew Garner,Jeffrey B. Matthews,Simon Rune,Andre L. Blum

DOI: https://doi.org/10.1177/106002809002401216

1990-12-01

DICP

Abstract:Sixty-seven invited participants involved in the development, evaluation, and use of therapies for acid-peptic disorders participated in a meeting to discuss the scientific basis for healing actions of ulcer drugs and the prospects for future developments (“Realities of Mucosal Protection in the Upper Gastrointestinal Tract”, Lausanne, Switzerland, November 8–10, 1987). Eighty-one key statements were prepared and subsequently analyzed on the basis of a voting system. Of the 45 statements that dealt with existing therapies, only 3 statements showed positive consensus (agreement of two-thirds or more of voters) about mechanisms of ulcer healing. Participants agreed that both (1) hydrogen/potassium adenosine triphosphatase inhibitors and (2) histamine H 2 antagonists healed ulcers solely by acid inhibition, and (3) that sucralfate works by topical action. Substantial uncertainty about the mechanisms by which bismuth compounds and antacids heal ulcers was noted as well as their wide range of effects. The mechanism of ulcer healing by prostaglandins and the clinical relevance of antiulcer effects of drugs demonstrated in acute studies with animals were also controversial. There was greater agreement among participants about unexplored drug effects that might produce ulcer healing. Of the 36 such mechanisms surveyed, the most support went to therapies aimed at enhancement of mucosal blood flow, epithelial restitution, and mucosal alkaline secretion or inhibition of luminal pepsin activity. The diversity of opinions among participants suggests a high level of empiricism in the development of ulcer healing drugs apart from those that inhibit acid secretion. This empiricism probably arises from inadequate understanding of processes of mucosal injury and repair.
[New clinical data on erythropoietin therapy of cancer patients with anemia. Summary of the major presentations at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, 2005].

I. Láng

Magyar Onkológia

Abstract:Anemia of patients with malignancy might have various reasons. No matter if its background is the underlying tumorous disease or chemo- and/or radiotherapy, it can cause fatigue, malaise, it certainly decreases the patients' quality of life and, furthermore, shortens their survival. Chronic hypoxia caused by anemia promotes tumor progression by several mechanisms e.g. by enhancing angioneogenesis by the production of VEGF. At the same time it decreases the efficacy of chemo- and radiotherapy. Therefore, prevention and/or correction of chemo/radiotherapy-induced anemia is a major goal of modern oncotherapy.

[Current therapy of peptic ulcer].

Pharmacological Treatment of Peptic Ulcer Disease

Recent Advances in Molecular Pathways and Therapeutic Implications for Peptic Ulcer Management: A Comprehensive Review

Unravelling Peptic Ulcers: Comprehensive Insights into Etiology, Diagnosis, Screening Techniques, and Treatment

Maternal consequences of caesarean section. A retrospective study of intra-operative and postoperative maternal complications of caesarean section during a 10-year period.

Peptic Ulcer: Chapter Closed?

Therapeutic Management of Recurrent Peptic Ulcer Disease

Eradication of Helicobacter pylori: recent advances in treatment

Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options

Gastrointestinal Conditions: Peptic Ulcer Disease

Treatment of Helicobacter pylori infection: Current and future insights

Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice

Actualization of the modern approach to the treatment of gastric ulcer

Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review

An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults

From Lab to Nature: Recent Advancements in the Journey of Gastroprotective Agents from Medicinal Chemistry to Phytotherapy

Comprehensive insights on treatment modalities with conventional and herbal drugs for the treatment of duodenal ulcers

Turn over the new leaf of the treatment in peptic ulcer bleeding: a review of the literature

Current and Future Drugs for Acid-Peptic Disease: A Plethora of Opinions on Possible Mechanisms of Action

[New clinical data on erythropoietin therapy of cancer patients with anemia. Summary of the major presentations at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, 2005].